|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 531.00 JPY | -2.21% |
|
+29.51% | - |
| 07-02 | Innovacell Secures U.S. Clearance for Global Phase III Cell Therapy Clinical Trial | MT |
| 05-13 | Innovacell Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| Market Cap | 24.49B 151M 132M 122M 113M 215M 14.36B 218M 1.46B 569M 7.08B 568M 556M | P/E 2026 * |
-6.66x | P/E 2027 * | -6.28x |
|---|---|---|---|---|---|
| Enterprise Value | 24.49B 151M 132M 122M 113M 215M 14.36B 218M 1.46B 569M 7.08B 568M 556M | EV / Sales 2026 * |
24.5x | EV / Sales 2027 * | 22.7x |
| Free-Float |
52.14% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -2.21% | ||
| 1 week | +29.51% | ||
| Current month | +29.51% | ||
| 1 month | -25.21% | ||
| 3 months | -36.94% |
| 1 week | 401 |  | 665 |
| 1 month | 377 | | 710 |
| Current year | 377 | | 1,248 |
| 1 year | 377 | | 1,248 |
| 3 years | 377 | | 1,248 |
| 5 years | 377 | | 1,248 |
| 10 years | 377 | | 1,248 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jason Sieger
CEO | Chief Executive Officer | 43 | 01/03/2025 |
Colin Lee Novick
CEO | Chief Executive Officer | 45 | 01/03/2022 |
Yasushi Hosono
DFI | Director of Finance/CFO | 59 | 01/07/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 56 | 01/04/2021 | |
Yasushi Hosono
BRD | Director/Board Member | 59 | 01/07/2021 |
Colin Lee Novick
BRD | Director/Board Member | 45 | 01/07/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.21% | +29.51% | - | - | 151M | |
| +2.96% | +3.01% | +59.87% | +173.31% | 1,102B | |
| +3.05% | +5.23% | +72.11% | +67.81% | 643B | |
| -0.04% | +1.20% | +35.72% | +87.93% | 450B | |
| +0.90% | -2.07% | +27.62% | +22.57% | 336B | |
| -1.05% | -0.76% | +28.70% | +47.94% | 288B | |
| -2.90% | +1.14% | -27.88% | -40.74% | 222B | |
| +0.45% | +1.65% | +25.65% | +68.35% | 199B | |
| +5.21% | +7.93% | +21.99% | +83.23% | 169B | |
| +1.48% | -0.04% | -4.64% | -32.25% | 137B | |
| Average | -0.50% | +5.05% | +26.57% | +53.13% | 354.53B | |
| Weighted average by Cap. | -0.10% | +1.86% | +41.73% | +87.37% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1B 6.18M 5.41M 4.98M 4.62M 8.77M 586M 8.91M 59.73M 23.23M 289M 23.19M 22.69M | 1.08B 6.66M 5.83M 5.37M 4.98M 9.45M 632M 9.6M 64.39M 25.04M 312M 25M 24.46M |
| Net income | -3.46B -21.39M -18.72M -17.25M -15.99M -30.35M -2.03B -30.84M -207M -80.44M -1B -80.31M -78.57M | -3.81B -23.52M -20.58M -18.97M -17.58M -33.38M -2.23B -33.92M -227M -88.46M -1.1B -88.31M -86.39M |
| Net Debt | - | - |
Employees
48
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/07/26 | ¥531.00 | -2.21% | 218,500 |
| 07/07/26 | ¥543.00 | -15.55% | 722,900 |
| 06/07/26 | ¥643.00 | +18.42% | 9,600 |
| 03/07/26 | ¥543.00 | +17.28% | 12,900 |
| 02/07/26 | ¥463.00 | +11.84% | 209,400 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- 504A Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
